Ipsen S.A./€IPN
1D1W1MYTD1Y5YMAX
Capital at risk
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
- Ticker
- €IPN
- Sector
- Health
- Primary listing
- PAR
- Employees
- 5,535
- Headquarters
- Paris, France
- Website
- www.ipsen.com
Ipsen S.A. Metrics
BasicAdvanced
€13B
25.44
€6.17
0.32
€1.60
1.02%
Price and volume
Market cap
€13B
Beta
0.32
52-week high
€176.00
52-week low
€111.40
Average daily volume
88K
Dividend rate
€1.60
Financial strength
Current ratio
1.965
Quick ratio
1.712
Long term debt to equity
13.279
Total debt to equity
16.259
Dividend payout ratio (TTM)
25.71%
Interest coverage (TTM)
28.45%
Profitability
EBITDA (TTM)
1,493.6
Gross margin (TTM)
81.01%
Net profit margin (TTM)
11.95%
Operating margin (TTM)
27.38%
Effective tax rate (TTM)
27.00%
Revenue per employee (TTM)
€780,000
Management effectiveness
Return on assets (TTM)
10.27%
Return on equity (TTM)
11.44%
Valuation
Price to earnings (TTM)
25.44
Price to revenue (TTM)
3.019
Price to book
2.75
Price to tangible book (TTM)
6.66
Price to free cash flow (TTM)
11.83
Free cash flow yield (TTM)
8.45%
Free cash flow per share (TTM)
13.267
Dividend yield (TTM)
1.02%
Forward dividend yield
1.02%
Growth
Revenue change (TTM)
14.14%
Earnings per share change (TTM)
14.85%
3-year revenue growth (CAGR)
9.35%
10-year revenue growth (CAGR)
10.54%
3-year earnings per share growth (CAGR)
4.45%
10-year earnings per share growth (CAGR)
8.16%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
6.53%
Bulls say / Bears say
Ipsen delivered H1 2026 sales growth of 23.5% at constant exchange rates (20.4% reported), with core operating income up 28.8% to €845 m and margin expanding to 38.6%; the company raised full-year sales guidance to >20% at CER and margin guidance to >37%, highlighting robust operational leverage (FT)
Positive Phase III BEOND results announced for Dysport in both episodic and chronic migraine mark the first botulinum toxin to meet primary endpoints in these indications, positioning Ipsen for entry into a multi-billion dollar migraine prevention market (Reuters)
On June 29, 2026 Ipsen agreed to acquire U.S. biotech Kartos Therapeutics for an initial $450 m, adding a late-stage MDM2 inhibitor in myelofibrosis to its pipeline and leveraging its €1 billion net cash to drive future growth (Reuters)
Failure of the Phase III BOLD trial for Bylvay (odevixibat) in biliary atresia did not meet its primary endpoint of native liver survival versus placebo, derailing Ipsen’s efforts to expand its rare disease franchise and prompting a share drop (Reuters)
Ipsen’s 2026 guidance was underpinned by temporary generic lanreotide shortages supporting Somatuline; with generic competition anticipated to resume in H2 2026, the flagship product faces potential revenue erosion (Reuters)
In March 2026 Ipsen voluntarily withdrew Tazverik from all markets following emerging safety data from the SYMPHONY-1 trial, reducing its late-stage oncology portfolio and triggering impairments that will weigh on future earnings (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Upcoming events
No upcoming events
Funds containing Ipsen S.A.
AllUSDEURGBP
Fund name | Fund size | €IPN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.75% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.75% |
iShares Healthcare Innovation£DRDR | £1B | 0.75% |
iShares EURO STOXX Mid€DJMC | €572M | 0.73% |
iShares EURO STOXX Mid Cap£DJMC | £491M | 0.73% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.